27th March
2019– Destiny Pharma issued an announcement, which is summarized as
follows:
Destiny Pharma is
pleased to announce that it has appointed MedPharm as its expert partner to
develop new topical formulations of the Company’s novel XF-platform compounds.
These new treatments for dermal and ocular infections are part of its second
clinical programme to address the global problem of anti-microbial resistance
(AMR). MedPharm is a world leading contract provider of topical
and transdermal product design and formulation development services using
sophisticated in vitro models to de-risk development
programmes.
MedPharm will develop
new formulations containing Destiny Pharma’s XF-platform compounds for the
treatment of a number of topically treated infections, including diabetic foot
ulcers and ophthalmic infections.
Original website Link: